Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
Novel compounds targeting TACE, TNF-α, MMPs, and ADAMs address the need for effective inhibitors to treat inflammatory disorders by reducing cartilage degradation, offering a therapeutic solution for osteoarthritis and rheumatoid arthritis.
Patent Information
- Application Number
- PCT/US2005/019131
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2004-06-02
- Filing Date
- 2005-06-01
- Publication Date
- 2005-12-22
AI Technical Summary
Current treatments for inflammatory disorders, such as osteoarthritis and rheumatoid arthritis, lack effective inhibitors for matrix metalloproteinases (MMPs), disintegrin and metalloproteases (ADAMs), and tumor necrosis factor alpha-converting enzyme (TACE) that can prevent the degradation of cartilage and alleviate associated pathological conditions.
Development of novel compounds with a specific structural formula that inhibit TACE, TNF-α, MMPs, and ADAMs, which can be used in pharmaceutical compositions to treat and prevent diseases associated with these enzymes, thereby reducing cartilage degradation and inflammation.
The compounds effectively inhibit the activity of TACE, TNF-α, MMPs, and ADAMs, providing therapeutic benefits in treating inflammatory disorders by reducing cartilage degradation and alleviating symptoms of osteoarthritis and rheumatoid arthritis.
